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a b s t r a c t
Cytokines mediate and control immune and inﬂammatory responses. Complex interactions exist among
cytokines, inﬂammation, and the innate and adaptive immune responses in maintaining homeostasis,
health, and well-being. On-demand, local delivery of anti-inﬂammatory drugs to target tissues provides
an approach for more effective drug dosing while reducing the adverse effects of systemic drug delivery. This work demonstrates a proof-of-concept theranostic approach for inﬂammation based on analytekissing induced signaling, whereby a drug (in this report, aspirin) can be released upon the detection
of a target level of a proinﬂammatory cytokine (i.e., interferon-γ (IFN-γ )) in real time. The structureswitching aptamer-based biosensor described here is capable of quantitatively and dynamically detecting
IFN-γ both in vitro and in vivo with a sensitivity of 10 pg mL−1 . Moreover, the released aspirin triggered
by the immunoregulatory cytokine IFN-γ is able to inhibit inﬂammation in a rat model, and the release
of aspirin can be quantitatively controlled. The data reported here provide a new and promising strategy for the in vivo detection of proinﬂammatory cytokines and the subsequent therapeutic delivery of
anti-inﬂammatory molecules. This universal theranostic platform is expected to have great potential for
patient-speciﬁc personalized medicine.
Statement of Signiﬁcance
We developed an adaptive in vivo sensing device whereby a drug, aspirin, can be released upon the detection of a proinﬂammatory cytokine, interferon-γ (IFN-γ ), in real time with a sensitivity of 10 pg mL−1 .
Moreover, the aspirin triggered by IFN-γ depressed inﬂammation in the rat model and was delivered indirectly through blood and cerebrospinal ﬂuid or directly to the inﬂammation tissue or organ without
adverse gastrointestinal effects observed in the liver and kidney. We envision that, for the ﬁrst time, patients with chronic inﬂammatory disease can receive the right intervention and treatment at the right
time. Additionally, this technology may empower patients to monitor their personalized health and disease management program, allowing real-time diagnostics, disease monitoring, and precise and effective
treatments.
© 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
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Inﬂammation is a self-protection defense mechanism that is
critical to combat harmful stimuli (e.g., pathogens) and initiate
the healing process. However, under many conditions, the inﬂammatory response becomes chronic and leads to signiﬁcant
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tissue/organ damage. [1] Recently, increasing evidence demonstrates that an abnormal inﬂammatory response is closely associated with many cancers [2] and numerous autoimmune diseases
[3] including rheumatoid arthritis, atherosclerosis, inﬂammatory
bowel disease, systemic lupus erythematosus, type 2 diabetes, and
Alzheimer’s disease. Inﬂammation is caused by a number of physiological reactions triggered by the immune system in response to
a physical injury or an infection. However, the precise source of
the inﬂammatory stimulus is often unknown and, even if known,
may be diﬃcult to remove or inhibit. Thus, interest has been
shown toward therapeutically targeting the inﬂammatory response
to inhibit and limit disease progression. Ongoing disease management in the context of chronic inﬂammation is increasing, with
major unmet needs in the era of precision diagnostics and treatment. [4] Although there has been success with anti-inﬂammatory
therapy in chronic diseases such as rheumatoid arthritis, there are
considerable limitations because of the toxicity associated with
treatment and variation in patient response. In particular, as the
inﬂammatory response is critical for host homeostasis, the challenges of redundancy, compensation by the host, and the necessity
for basal immune function often narrow the risk-to-beneﬁt ratio
of anti-inﬂammatory drugs. Thus, it is essential for patients with
chronic inﬂammatory disease to receive treatments that target the
abnormal immune response in a timely and precise manner.
Precision medicine is a medical model that aims for the customization of healthcare with medical decisions, practices, and
products tailored to the individual patient. On the basis of the
knowledge of disease mechanisms, precision medicine generally
combines diagnosis and treatment to achieve optimal disease management [5]. The paradigm of intelligent personalized medicine
holds the promise to revolutionize healthcare by delivering “the
right drug, at the right dose, and at the right time” [6]. As stated
above, precision medicine is particularly important in addressing
individual inﬂammation [7] and inﬂammation-based diseases
[8]. To meet the needs of precision medicine with an approach
that can be applied to many individuals without the need for
specialized and costly individualized therapies, we report here the
development of a technology that meets this targeted goal.
In this report, we have utilized aptamer technology to monitor and measure the host inﬂammatory response. Aptamers are
oligonucleotides or peptides that can bind to their targets with
high aﬃnity and speciﬁcity [9]. Aptamers, as a potent and speciﬁc
alternative to antibodies, not only have all of the advantages of
speciﬁc interactions with their target molecules but also have
unique merits including thermal stability, low production cost,
lack of immunogenicity, ease of chemical synthesis and modiﬁcation, rapid tissue penetration, and unlimited applications in
diagnostics and therapeutics [10]. Aptamer beacons can reversibly
load and release a molecular cargo upon binding to a speciﬁc
target analyte [11]. This feature can be deployed for real-time
sensing, [12–14] computing, actuating, or drug delivery [15–17],
thus moving aptamer-based precision medicine closer to reality.
For example, Ricci and coworkers demonstrated the construction
of a modular DNA-based nanomachine that can reversibly load
and release the nucleic acid upon binding to a speciﬁc antibody.
[18] The antibody-powered DNA nanomachines have demonstrated
great potential in applications including controlled drug release,
point-of-care diagnostics, and personalized medicine. [19]
Cytokines, which act as mediators and modulators in the
differentiation, sensitization, and activation of various immune
cells, are bioactive soluble proteins produced by the immune
and nonimmune cells that are directly required for normal host
immune function as well as disease initiation and progression
[20,21] The elevated concentration of cytokines in the host serum
or at speciﬁc locations (e.g., a solid tumor) normally indicates the
activation of inﬂammation or other steps in disease progression
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[22]. Thus, for patients with chronic inﬂammatory disease or
cancer to receive treatment at the right time, it will be essential to monitor cell functions and cell-to-cell communication, as
measured by cytokine expression, and then initiate precision drug
delivery according to the in vivo cytokine concentration. However,
there are many challenges in meeting this objective, including the
fact that cytokine-related immune reactions are often extremely
dynamic and may be transient and/or localized in nature. [22] In
addition, cytokines are either not detectable or only expressed at
picomolar concentrations in body ﬂuid or tissues of healthy individuals. We have successfully achieved the sensitivity in pg mL−1
range of cytokine measurement by introducing nanomaterials to
the sensing interfaces. [23–25] To realize real-time detection of
cytokines, we have developed different sensing platforms based on
aptamers for the detection of cytokines. [26,27] Taking advantage
of the structure-switching property of aptamers, we recently
reported a structure-switching aptamer-based recyclable in vivo
sensing device for the continuous detection of the cytokine IFN-γ
in mice at a sensitivity of 1 pg mL−1 . [28] In this system, redox
probes were loaded in the hairpin part of the aptamer, which
were released upon the detection of IFN-γ . It was observed that
the released redox probes could be reloaded to aptamers to realize
the regeneration of the sensing interfaces. Inspired by this system,
we are interested in developing a smart stimuli-responsive system
that can enable continuous cytokine monitoring with a high
sensitivity while drug delivery is triggered when in vivo cytokine
levels reach a pathological or “alarmed” level.
Nonsteroidal anti-inﬂammatory drugs such as aspirin are
among the earliest agents used in western medicine. Pharmacological effects of aspirin are thought to occur through covalent
modiﬁcation of cyclooxygenase (COX) [29]. In this report, we
developed an adaptive in vivo sensing devices (Fig. 1) based on
a glassy carbon (GC) rod, which provides an approach whereby a
drug, aspirin, can be released upon the detection of a target level
of the proinﬂammatory cytokine interferon-γ (IFN-γ ) in real time.
The sensor described here is capable of quantitatively and dynamically detecting IFN-γ both in vitro and in vivo at a sensitivity of
10 pg mL−1 . Moreover, the released aspirin triggered by IFN-γ
depresses inﬂammation in a rat model. We demonstrate here that
aspirin loaded in aptamers and delivered indirectly through blood
and cerebrospinal ﬂuid or directly to a tissue or organs can avoid
adverse gastrointestinal effects and other adverse effects observed
in the liver and kidney. With our approach, we aim, for the ﬁrst
time, that patients with chronic inﬂammatory disease can receive
the right intervention and treatment at the right time. Additionally,
this technology may empower patients to precisely monitor their
personalized health and disease management through real-time
diagnostics and disease/treatment monitoring.
2. Experimental section
2.1. Chemical and materials
Aspirin,
streptavidin,
Tris(hydroxymethyl)aminomethane
(Tris), hydrochloric acid, potassium chloride, magnesium
chloride, sodium nitrite, potassium ferricyanide, 1-ethyl-3(3-dimethylaminopropyl)carbodiimidehydrochloride
(EDC),
4carboxyphenyl aryldiazonium salt, N-hydroxysuccinimide (NHS),
2-(N-morpholino)ethanesulfonic acid (MES), and lipopolysaccharide (LPS) were purchased from Sigma-Aldrich. Phosphate buffer
solution contained 0.05 M KCl and 0.05 M K2 HPO4 /KH2 PO4 adjusted to pH 7.4 with NaOH or HCl solution. Aqueous solutions
were prepared using Milli-Q water. Recombinant human IFN-γ
was purchased from R&D Systems (Minneapolis, MN, USA). All
DNA was produced by Shanghai Sangon Biotech Co. Ltd. (Shanghai,
China). The sequence of the hairpin aptamer probe (red color is
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Fig. 1. Schematic of the fabricated adaptive in vivo device for monitoring IFN-γ and IFN-γ -triggered drug delivery.

the sequence that has aﬃnity to both human and murine IFN-γ )
was 5 -Fc-C6 -GGG GTT GGT TGT GTT GGG TGT GTC CAA CCC
C-C3 -biotin-3 . Tris-HCl buffer contained 100 mM Tris-HCl, 100 mM
NaCl, 1 mM MgCl2 , and 5 mM KCl, pH at 7.4.
2.2. Apparatus
All electrochemical experiments were conducted with CHI660E
(CH Instruments, Inc., Shanghai). GC electrodes were 3 mm disks
embedded in epoxy resin (Gaoss Union, China). All experiments
used a Pt secondary electrode and an SCE (saturated calomel electrode) reference electrode. X-ray photoelectron spectra (XPS) were
recorded from GC plates on a VG MultiLab 20 0 0 spectrometer with
a monochromatic Al Kα source, hemispherical analyzer, and multichannel detector. The spectra were analyzed using XPSPEAK41
software. UV–Vis absorption data were recorded on a Shimadzu
UV–Vis spectrophotometer model 2450.
2.3. Preparation of aptamer(aspirin) probes
To prepare the aptamer(aspirin) probes, 100 μL of 20 μM
aspirin-containing water solution was mixed with 100 μL of 5 μM
IFN-γ aptamer probe solution, and the mixture solution was incubated in Tris-HCl buffer solution (pH = 7.4) at room temperature
for 24 h. After reaction, the sample was ﬁltered using a centrifugal
ﬁlter (Millipore, Amicon Ultra-0.5 mL 30 K) to wash and purify
the aptamer (aspirin). The achieved aptamer(aspirin) probes were
stored at 4 °C before use.
2.4. Preparation of the sensing interface for detection of IFN-γ
The GC electrodes were cleaned by being hand-polished on
microcloth pads in 1.0, 0.3, and 0.05 μm alumina slurries in succession (made from dry alumina and water), and then they were
thoroughly rinsed with water and sonicated in water for 1 min.
Before modiﬁcation with aryldiazonium salts, the GC electrode was
dried under a stream of nitrogen followed by exposure to 0.5 M
HCl solution containing 1 mM corresponding diazonium salts,
which was degassed for 15 min with nitrogen ﬂow in an ice bath.
The electrochemical reductive modiﬁcation of the GC electrodes
with 4-carboxyphenyl (HOOC-ph-GC) was achieved by scanning in
the potential range from 0.6 V to −1.0 V for 2 cycles with a scan
rate of 100 mV s−1 . After washing with water and ﬁnally drying

under a stream of nitrogen, the carboxylic group-terminated
GC surfaces (GC-ph-COOH) were immersed in 10 mM EDC and
40 mM NHS prepared in 100 mM MES buffer solution for 1 h to
activate the carboxylic acid group on the electrode surface. After
rinsing with deionized water and Tris-HCl buffer solution, the activated electrodes were dried under N2 , followed by incubation in
200 μg mL−1 streptavidin (STR) in pH=7.4 Tris-HCl buffer solution
at room temperature for 4 h to obtain GC-ph-STR surfaces. Finally,
GC-ph-STR surfaces was immersed into 5 μM aptamer(aspirin)
solution for 1 h to generate GC-ph-STR-aptamer(aspirin) surfaces
for the detection of IFN-γ .
2.5. Electrochemistry measurement of IFN-γ using the
aptamer(aspirin)-modiﬁed sensing interface
The prepared GC-ph-STR-aptamer(aspirin) surfaces were incubated with 10 μL Tris-HCl buffer containing IFN-γ at various concentrations for 30 min at room temperature. Then the squarewave
voltammetry (SWV) of aptamer(aspirin)-modiﬁed GC electrodes
after exposure to IFN-γ was collected using a CHI660E workstation
by scanning the potential between −0.2 V and 1.2 V with a step potential of 4 mV, a frequency of 10 Hz, and an amplitude of 40 mV.
Real-time measurement was carried out by chronoamperometry in
a series of different concentrations of IFN-γ by ﬁxing the potential
at 0.2 V for 50 0 0 s for Fc and 0.9 V for 50 0 0 s for aspirin.
2.6. Cell culture
Informed consent in this study was obtained under approved
Animal Research Ethics Committee protocols with the ethics
number 2017065. Peripheral blood mononuclear cells (PBMCs)
were purchased from Procell (Wuhan, China). The cells were
cultured in a T25 cm2 ﬂask in RPMI-1640 medium supplemented
with 10% heat-inactivated human serum AB, 10 U mL−1 of penicillin, 10 0 0 U mL−1 IL-2, 1100 μg mL−1 of streptomycin,10 μg mL−1
gentamicin, 2 mM gentamine, and 25 mM HEPES. The cells, at a
concentration of 1 × 106 /mL, were incubated in a 6-well plate at
37 °C and 5% CO2 . To harvest, the cells at 80–90% conﬂuence were
washed twice with Dulbecco’s phosphate-buffered saline, followed
by trypsinization using 2 mL of trypsin to detach the cells from
the ﬂask. The trypsin was neutralized by adding 4 mL of fresh
supplemented medium, and the harvested cells were resuspended
in complete RPMI-1640 medium, transferred into a centrifuge
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Fig. 2. (a) Electrochemistry of aptamer(aspirin) probes and aspirin in pH = 7.4 Tris–HCl buffer solution. (b) UV–Vis spectra of aptamer (5 μM), aspirin (50 μM), and aptamer(aspirin) (5 μM) in pH = 7.4 Tris–HCl buffer solution.

tube, and centrifuged at 1500 rcf for 10 min. The supernatant
was discarded, and the cells were resuspended in fresh medium.
For the preparation of IFN-γ samples, the cells at a density of
1 × 106 /mL were suspended in 1 mL of warm complete medium
containing 0.1 μg mL−1 LPS to induce IFN-γ expression at 0 h, 2 h,
4 h, 6 h, 8 h, and 20 h. The supernatants from cells were collected
in triplicate. The Nunc MaxiSorp 96-well plate and the Galaxy
plate reader were used for subsequent ELISA.
2.7. Animal model of endotoxemia
Adult wild-type Sprague Dawley male rats were purchased
from Vital River Corporation (Beijing, China). The rats were randomly divided into two groups (number of animals/group) as (1)
the control group (no electrode implant) and (2) the electrode
implant group for corresponding time points at 0 h, 1 h, 6 h, 12 h,
and 24 h after induction of endotoxemia. Surgery was performed
under anesthesia by inhalation of 4% isoﬂuorane, and the animals were maintained in 2% isoﬂuorane. To induce endotoxemia,
LPS (5 mg/kg) was injected intraperitoneally. After injection, the
aspirin-loaded electrodes were implanted into the subcutaneous
pockets on the back of the animals, and the skin was closed
with sutures. The animals were euthanized with CO2 at 0 h, 1 h,
6 h, 12 h, and 24 h, and the blood and electrodes were harvested
for analysis. As the lung is the moderately affected tissue in
endotoxemia, the lungs were collected for histological analysis
at 24 h.
2.8. ELISA assays
To evaluate the effects of aspirin-loaded electrodes, the blood
specimens of the two groups of rats and the interstitial ﬂuid of
the lung were collected and processed immediately for further
cytokine measurement. The levels of inﬂammatory cytokines (IL-6
and IFN-γ ) in the serum and ﬂuid were measured using the
enzyme-linked immunosorbent assay (ELISA) kit (Boster Biological
Technology, China) according to the manufacturer’s instructions.
2.9. Histology and immunohistochemistry assay
The lungs from experimental groups of rats were collected,
ﬁxed in 10% formalin overnight, embedded in paraﬃn, and sectioned at a thickness of 5 μm. The sections were deparaﬃnized,
rehydrated, and stained with hematoxylin and eosin (H&E). Moreover, the sections were also stained with a neutrophil marker (Ly6 G antibody, Thermo Fisher Scientiﬁc, USA) for immunohistochemistry measurement. The procedure was carried out according to the
protocol of the atreptavidin-peroxidase immunohistochemical kit

with antimouse Ly-6 G/Gr-1 antibodies (1:200, Santa Cruz Biotechnology), followed by antimouse IgG-horseradish peroxidaseconjugated secondary antibody (1:200, Jackson), and the 3,3 diaminobenzidine (DAB) coloration kit (Zhongshan Bioengineering
Co. Ltd, Beijing, China). The immunostaining results were observed
after samples were treated with a hematoxylin counterstain. For
histopathological analyses, four inﬂammatory parameters were
scored independently from 0 to 4 for each section as previously described [30]: alveolar congestion; (b) hemorrhage; (c) neutrophilic
inﬁltration, and (d) thickness of the alveolar wall and hyaline
membrane formation. Each category was graded on a 0- to 4-point
scale: 0 = no injury; 1 = injury up to 25% of the ﬁeld; 2 = injury
up to 50% of the ﬁeld; 3 = injury up to 75% of the ﬁeld; and
4 = diffuse. [31] Injury slides were randomized, read blindly, and
scored for each. The inﬂammatory cell number and the positive
area of IHC staining were evaluated with Image-Pro-Plus software.

2.10. Statistical methods
All experiments were performed in at least triplicate, and
the results were presented as the mean and standard deviation
of the three replicates. Statistical analyses were performed with
both Excel and Origin. We considered p < 0.01 as statistical
signiﬁcance.
3. Results and discussion
3.1. Characterization of aptamer (aspirin) probes
Initially, the SWVs of GC electrodes in pH=7.4 Tris-HCl buffer
solution after applying 10 μL of 20 μM aspirin, 5 μM aptamer,
and 5 μM aptamer(aspirin) probe were determined. As shown in
Fig. 2, a pair of redox peaks was observed for GC electrodes after
applying the aspirin solution at 0.9 V. However, two pairs of peak
current were observed after applying the aptamer(aspirin) probe
on the GC electrode at 0.2 V and 0.9 V, representing ferrocene and
aspirin, respectively, suggesting that aspirin has been embedded
into the stem part of the aptamer probe as shown in the schematic
design in Fig. 1. This result was conﬁrmed by UV–Vis absorption
spectroscopy (Fig. 2b), as one absorption peak, centered at 260 nm,
was observed in the UV–Vis absorption spectra of aptamer and
aptamer (aspirin). Another absorption peak, centered at 295 nm,
was observed in the UV–Vis absorption spectra of both aspirin
and aptamer (aspirin) [32]. This result suggested that aspirin
was successfully intercalated into the double-stranded 5 -GC-3
sequences of the aptamer by the force of π –π stacking to conﬁrm
the aptamer (aspirin) probes [33]. Under optimized conditions, we
quantiﬁed the number of aspirin molecules loaded on the aptamer
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Fig. 3. (a) C1s spectra for GC-ph-COOH. (b) N1s spectra for GC-ph-COOH. (c) C1s spectra for GC-ph-STR-aptamer(aspirin). (d) N1s spectra for GC-ph-STR-aptamer(aspirin).
(e) P2p spectra for GC-ph-STR-aptamer(aspirin). (f) GC-ph-STR-aptamer(aspirin) after exposure to 500 pg mL−1 IFN-γ for 30 min followed by washing. (g) XPS survey spectra
for stepwise modiﬁcation of the sensing interfaces.

complex according to the modiﬁed protocol [34]. Supplementary
Figure S1 shows the SWV curves that were obtained by reacting
100 μL of 5 μM aptamer solution with different concentrations
of 100 μL aspirin solution for 24 h. The oxidation peak current of
aspirin increased with the increase in the concentration of aspirin
from 5 to 100 μM, and it reached a plateau when a concentration
of more than 20 μM was added. Thus, the optimized concentration
of the aspirin solution was 20 μM (Supplementary Figure S1 a).
On the basis of the calibration curve between aspirin concentration and absorbance (Supplementary Figure S1 b), the maximal
absorbance of the aspirin was observed when the ratio of aspirin
and aptamer reached 3:1, suggesting three aspirin molecules could
intercalate into one aptamer. To provide more information about
the loading capacity of aspirin on each electrode, the optimized
electrode was heated to 95 °C to release all the encapsulated
aspirin as a result of DNA denaturation. The released aspirin
was measured by UV–Vis absorption spectroscopy, indicating the
amount of aspirin on each electrode was approximately 3.1 μmol.
3.2. XPS characterization of the stepwise fabricated sensing interface
XPS measurements were carried out to further characterize GC
surfaces after stepwise modiﬁcation with different species. C1s has

two peaks at around 284.7 eV and 288.9 eV. The peak at 288.9 eV
is assigned to the carbon of the carboxyl groups on the surface of
GC-ph-COOH (Fig. 3a) [35]. However, N1s has two peaks at about
400.2 eV, which are assigned to unreacted carboxyphenyl (Fig. 3b).
For the GC-ph-STR-aptamer(aspirin) surface, C1s has four peaks
at around 284.4 eV, 286.1 eV, 287.7 eV, and 291.2 eV (Fig. 3c). The
peak at 286.1 eV is assigned to the –C–O–C- species in streptavidin
[36]. The peak at 287.7 eV is assigned to the peptide bond formed
by the interaction between -COOH from 4-carboxyphenyl on
electrodes and amine from streptavidin [26]. The peak at 291.2 eV
is assigned to the -COO–CH3 - species in aspirin [33]. In addition,
the peak at 133.6 eV was assigned to phosphorus in the aptamer
DNA (Fig. 3e) [37]. The results suggest that aptamer(aspirin) was
successfully attached onto the GC-ph-COOH surface. However,
two peaks at 399.7 eV and 401.2 eV were observed in the N1
species on the GC-ph-STR-aptamer(aspirin) surfaces, and these
were assigned to unreacted EDC and NHS, respectively (Fig. 3d).
However, the peak of C1s at 291.2 eV disappeared after exposure
of the aptamer(aspirin)-modiﬁed GC surfaces to 500 pg mL−1
IFN-γ , suggesting that the GC-ph-STR-aptamer(aspirin) surfaces
could release aspirin in the presence of IFN-γ (Fig. 3f). Fig. 3g
illustrates XPS survey spectra conﬁrming the successful stepwise
modiﬁcation of the sensing interfaces.
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3.3. Electrochemistry characterization of the stepwise fabricated
sensing interface
The stepwise fabrication of the GC-ph-STR-aptamer(aspirin)
sensing surfaces was also characterized by electrochemistry. The
ﬁrst sweep of the electrochemical modiﬁcation of GC with the
4-carboxyphenyl groups (Supplementary Figure S1 c) produced an
irreversible reduction wave at −0.4 V corresponding to the reduction of the carboxyl acid group to a radical anion. On the second
scan, the ﬁrst wave at −0.4 V vanished, suggesting inhibition of
the electron transfer by the 4-carboxyphenyl group grafted on the
GC surfaces. After the modiﬁcation of 4-carboxyphenyl layers, the
redox peaks of Fe(CN)6 3- observed with bare GC electrodes were
completely suppressed (Supplementary Figure S1 d), giving strong
evidence that a monolayer of 4-carboxyphenyl, which blocked the
access of redox molecules to the GC electrode, had formed on the
GC surfaces. The SWV curves of bare GC, HOOC-ph-GC, STR-GC, and
aptamer(aspirin)-GC in PBS buffer are displayed in Supplementary
Figure S1 e. A redox peak was observed at 0.8 V, which is the characteristic peak of STR, suggesting that STR was successfully modiﬁed onto the electrode surface [38]. After modiﬁcation of the aptamer(aspirin) onto the GC electrode to form aptamer (GC) through
the interaction between biotin and streptavidin, a symbolic peak
from Fc was observed in SWV (Supplementary Figure S1 f).
3.4. In vitro real-time monitoring of IFN-γ and IFN-γ -triggered
aspirin release using the GC-ph-STR-aptamer (aspirin) interface
After the successful fabrication of the GC-ph-STRaptamer(aspirin) sensing interface, the electrochemical response
of the GC-ph-STR-aptamer(aspirin) sensing interface to IFN-γ was
analyzed (Fig. 4). In the absence of IFN-γ , there was an obvious
redox peak observed at 0.2 V, which belongs to a ferrocene-free
aptamer (Fig. 4a). According to the redox peak of Fc in Fig. 4a, the
surface coverage of the aptamer was calculated to be 5.1 x However, the peak at 0.2 V disappeared, and a pair of redox peaks at
approximately 0.9 V, characteristic of aspirin, appeared after exposure to IFN-γ followed by extensive washing. The electrochemical
signal switching was due to the binding of IFN-γ to the loop part
of the aptamer, leading to the opening of the stem part of aptamer,
followed by the subsequent release of aspirin molecules into the
environment. This then induced the electric communication between the released aspirin and the underneath GC electrode,
resulting in the subsequent Faradic current at 0.9 V. Furthermore,
Fc redox molecules labeled on aptamers were dissociated away
from the electrode surface because of the conﬁguration change
of the aptamer, resulting in decreased electron transfer eﬃciency
between the aptamers and underlying electrodes and, consequentially, switching off of the current. To conﬁrm this hypothesis,
SWV, as a more sensitive electrochemical technique, was used to
quantitatively monitor the electrochemical response (Fig. 4b).
The real-time sensor described here is based on analytekissing-induced structure-switching aptamers and subsequent
aspirin-releasing signaling molecules. Thus, any factors that affect
the binding of aspirin to the aptamer will contribute to the sensor performance. To investigate environmental inﬂuences on the
sensor, the effect of pH, salt concentration, and temperature on
the stability of the GC-ph-STR-aptamer(aspirin) sensing interface
(the release of aspirin) was analyzed (Supplementary Fig. S2). It
was observed that under acidic conditions, the DNA was deprived
of purines leading to the release of aspirin. Thus, less aspirin was
released after reaction with IFN-γ , resulting in a smaller current.
However, when the pH reached 8 (Supplementary Fig. S2 a), the
aptamer was denatured by the alkaline condition, and that neutralized the charge of acids but caused the hydrolysis of bases upon
prolonged treatment. Consequently, pH 7.4 was found to be the
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optimized condition required to monitor IFN-γ levels. The sensing
provided the optimized performance when the salt concentration
was 100 mM (Supplementary Figure S2 b). In addition, increasing
the temperature from 25 °C to 95 °C also caused the release of
aspirin molecules before reaction with IFN-γ . Heating the aptamer(aspirin) solution to 95 °C leads to DNA denaturation by separating a double strand into two single strands, thus subsequently
releasing the incorporated aspirin molecules, a process that occurred when the hydrogen bonds between the DNA strands were
broken [39]. Consequently, the stem part of the aptamer opens
and releases the incorporated aspirin molecules (Supplementary
Figure S2 c). However, the GC-ph-STR-aptamer(aspirin) sensing
interface performed well at physiological temperature, i.e., 37 °C,
which makes it stable under physiological conditions. The reaction
time with IFN-γ was also investigated by monitoring the change
in current with the reaction time (Supplementary Fig. S2 d). The
current increased with the reaction time and reached a plateau
when the reaction time was 60 min. The current at 30 min was approximately 90% of that observed at 60 min and thus was selected
as the optimized reaction time. Under optimized conditions, the
peak current corresponding to IFN-γ decreased with the increase
in IFN-γ concentration (Fig. 4c). There was a linear range of 10–
500 pg mL−1 for the detection of IFN-γ with the lowest detection
limit of 10 pg mL−1 in Tris buffer. As determined from the midpoint of the IFN-γ calibration curve shown in Fig. 4d, the aﬃnity
constant between IFN-γ (molecular weight 16.9 kDa) and the aptamer(aspirin) was calculated to be approximately 5.3 × 1010 M − 1 .
The typical aﬃnity constant Ka for antigen–antibody reactions is in
the range of 108 to 1012 M−1 [40], and hence, the data presented
here indicate that the aptamer(aspirin) probe has a very high
aﬃnity to IFN-γ . Furthermore, the electrochemistry responsible
for the released aspirin was recorded (Fig. 4e), and the SWV peak
current increased with increasing IFN-γ concentration. The peak
current at approximately 0.9 V demonstrated a linear relationship
with the concentration of IFN-γ in the range of 0–500 pg mL−1 .
This observation indicates that aspirin was released, which can
be quantitatively measured according to the current change in
0.9 V. This further conﬁrms that our proof-of-concept system
for cytokine detection and cytokine-triggered drug delivery was
effective.
To investigate the real-time sensing capability of the GC-phSTR-aptamer(aspirin) interface, a chronoamperometry experiment
at a constant potential of 0.2 V (close to the oxidation potential
of Fc) was carried out by adding different concentrations of IFN-γ
under constant stirring (Fig. 5a). Fig. 5b shows the calibration
curve based on the chronoamperometry measurement. The linear
range obtained here was 10–500 pg mL−1 , which is comparable to
that obtained by SWV as shown in Fig. 3d. Upon the addition of
IFN-γ , the monitored current of the GC-ph-STR-aptamer(aspirin)
sensing interface decreased with the increase of the IFN-γ concentration. A chronoamperometry experiment at a constant potential
of 0.9 V (close to the oxidation potential of aspirin) was carried
out by adding different concentrations of IFN-γ under constant
stirring (Fig. 5c). Upon the addition of IFN-γ , the monitored
current of the GC-ph-STR-aptamer(aspirin), in contrast to the
current observed by a constant potential of 0.2 V, increased with
increasing IFN-γ concentration. This suggests that the presence
of IFN-γ induced the conﬁguration change of the aptamer and
the subsequent release of aspirin, resulting in increased current at
0.9 V. To conﬁrm the proposed mechanism of the analyte-induced
drug delivery, we measured the rate of aspirin release in the presence of IFN-γ . According to Chow’s method [41], the drug release
rate can be calculated using the equation K = ln(C /C0 ) / (t-t0 ). In
the presence of IFN-γ , the rate of aspirin release was calculated
to be 0.033 μM min−1 , suggesting a quantitatively controlled drug
release.
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Fig. 4. (a) Cyclic voltammetries and (b) Squarewave voltammetries of the GC-ph-STR-aptamer(aspirin) sensing interface in pH 7.4 Tris buffer before and after exposure to
500 pg mL−1 IFN-γ . (c) Spectrum of the Fc peak generated by the SWV of GC-ph-STR-aptamer(aspirin) after exposure to different concentrations of IFN-γ (0, 10, 50, 200,
30 0, 40 0, 50 0, 80 0, and 10 0 0 pg mL−1 ). (d) The relationship of the peak current of Fc at (c) with the log concentration of IFN-γ . (e) Spectra of the aspirin peak generated by
the SWV of GC-ph-STR-aptamer(aspirin) after exposure to different concentrations of IFN-γ . (f) The relationship of the peak current corresponding to aspirin in (e) with the
concentration of IFN-γ .

To investigate the selectivity of the fabricated sensor, seven
potentially interfering compounds, namely, bovine serum albumin (BSA, 2 mg mL−1 ), prostate-speciﬁc antigen (PSA, 1 μg mL−1 ),
cancer antigen 125 (CA-125, 1 μg mL−1 ), IL-6 (1 μg mL−1 ), TNFɑ (1 μg mL−1 ), IFN-α (1 μg mL−1 ), and IFN-β (1 μg mL−1 ), were
added to the detection buffer solution in the presence of IFN-γ
(500 pg mL−1 ) (Supplementary Figure S2 e). No signiﬁcant effect from these seven nonspeciﬁc proteins was detected. The
retained current percentage for all nonspeciﬁc proteins was above
90%, suggesting an insigniﬁcant degree of interference by these
molecules tested in relation to the control (<10%). The stability of
the sensing interface was also analyzed by incubating the GC-phSTR-aptamer(aspirin) sensing interface in Tris buffer for 1, 2, 3, 5,
10, 15, 20, 25, and 30 days at room temperature, respectively. The
electrochemistry was monitored at each time point (Supplementary Figure S2 e). Less than 5% of the signal was lost from Fc after
25 days, indicating that the GC-ph-STR-aptamer(aspirin) sensing
interface was stable for at least 25 days.

3.5. Detection of IFN-γ in a cellular microenvironment
The GC-ph-STR-aptamer(aspirin) sensing interface was tested
for the detection of IFN-γ secreted by PBMCs (Fig. 6). First, a
chronoamperometry experiment at a constant potential of 0.2 V
was carried out in a medium containing 1 × 106 cells under
stirring, to which IFN-γ , at concentrations of 10–10 0 0 pg mL−1 ,
was added (Fig. 6a). It was observed that the current decreased
continuously after adding IFN-γ until it reached a plateau when
the concentration of IFN-γ was 500 pg mL−1 . The calibration curve
for real-time measurement of IFN-γ in the cell culture medium
was plotted as shown in Fig. 6b. The supernatant of the 1 × 106
PBMCs was collected for IFN-γ analysis after LPS stimulation for 2,
4, 6, 8, and 12 h. The supernatant samples were subsequently analyzed by ELISA and prepared for the GC-ph-STR-aptamer(aspirin)
sensing interface. As shown in Fig. 6b, the concentration of IFN-γ
increased with the duration of the 10 ng mL−1 LPS treatment, and
the maximum level of 500 pg mL−1 IFN-γ was obtained after
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Fig. 5. (a) The current record as a function of time for GC-ph-STR-aptamer(aspirin) in pH = 7.4 Tris–HCl buffer solution at a constant potential of 0.2 V after adding IFN-γ at
different concentrations. (b) The calibration curve of the GC-ph-GO-aptamer (Ru) sensing interface obtained by the chronoamperometry in (a) and another two independent
measurements. (c) The current record as a function of time for GC-ph-STR-aptamer(aspirin) in pH = 7.4 Tris–HCl buffer solution at a constant potential of 0.9 V after adding
IFN-γ at different concentrations. (d) The calibration curve of the GC-ph-GO-aptamer(Ru) sensing interface obtained by the chronoamperometry in (c) and another two
independent measurements. (e) I-t curves of aspirin at different concentrations of IFN-γ . (f) The standard linear calibration curve of cytokine according to (e) and another
two independent measurements.

Fig. 6. (a) Chronoamperometry recording of GC-ph-STR-aptamer(aspirin) sensing cell culture media of PBMCs at a constant potential of 0.2 V after LPS treatment. (b) Calibration curve of the GC-ph-STR-aptamer(aspirin) sensing interface obtained by chronoamperometry in (a) and another two independent measurements. The inset in (b) is a
comparison of the IFN-γ secretion proﬁle between the presented sensor and the traditional ELISA after 10 ng mL−1 LPS stimulation.
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Fig. 7. Reduced Fc currents and increased aspirin currents measured in the blood of rats with inﬂammation using the GC-ph-STR-aptamer(aspirin) sensor. Currents generated
at constant potentials of 0.2 V (a) and 0.9 V (b) were measured.

Fig. 8. Relationship between peak current and implantation time, which was obtained by the SWV measurement of the GC-ph-STR-aptamer(aspirin) device after implantation
into the inﬂammatory rat model for different time points, in Tris–HCl buffer with the potential between 0 V and 0.5 V (a) and in Tris–HCl buffer containing 10 0 0 pg/mL of
IFN-γ with the potential between 0.7 V and 1.2 V (b). (a) Fc signal on the electrode and (b) the residual aspirin on the electrode. The inset shows the release proﬁle of aspirin
against the implantation time calculated from (b).

8 h LPS stimulation, a ﬁnding that was consistent to what we
previously reported. [30] A comparison of IFN-γ detection using
the proposed biosensor device and the traditional ELISA method
is included in the inset of Fig. 6b. The sensor reported herein and
ELISA displayed similar IFN-γ secretion patterns, suggesting that
the performance of the sensor was comparable with that of ELISA
for the detection of IFN-γ in a cell microenvironment.
3.6. Detection of IFN-γ and IFN-γ -triggered aspirin release in blood
samples
The performance of the GC-ph-STR-aptamer(aspirin) for the
detection of IFN-γ and simultaneous aspirin release was investigated in blood samples obtained from male rats intraperitoneally
injected with LPS to induce endotoxemia (designated “inﬂammatory rat”). Blood samples were collected using heparinized
capillary tubes at 0 h and 24 h after implantation. The GC-ph-STRaptamer(aspirin)-modiﬁed in vivo devices were incubated in 1 mL
of the blood collected from normal rats and the inﬂammatory
rat model for 1 h. Then 1 mL of Tris–HCl buffer was added, and
the chronoamperometry experiment at a constant potential of
0.2 V (Fc) and 0.9 V (aspirin) was performed utilizing these blood
samples. As shown in Fig. 7 and Supplementary Figure S3, the
monitored current of the GC-ph-STR-aptamer(aspirin) for the Fc
peak in the blood of normal rats was much higher than that
measured in the blood of the inﬂammatory rat model, while a
completely contrasting phenomenon was observed in the current
for the aspirin peak. This observation suggested that IFN-γ levels
in the blood of the inﬂammatory rat model were much higher than
those measured in the blood of normal rats. These results also
demonstrated that only IFN-γ in the blood of the inﬂammatory rat
model was able to release the aspirin from the GC-ph-STR-aptamer,
thereby changing the conﬁguration of aptamer to suppress the
electrochemical signal of Fc. This demonstrated the potential of

the GC-ph-STR-aptamer(aspirin) sensing device for the integrative
detection of pro-inﬂammatory signals and subsequent therapy.
3.7. Detection of IFN-γ and IFN-γ -triggered aspirin release in living
rats
To further investigate the in vivo performance of the GCph-STR-aptamer(aspirin) device for IFN-γ detection and aspirin
release, the electrodes were initially implanted into the subcutaneous tissue of rats treated with LPS for 0–24 h. Then the
withdrawn electrodes were measured by SWV in Tris-HCl buffer
with the potential between −0 V and 0.5 V and in Tris-HCl buffer
containing 10 0 0 pg mL−1 of IFN-γ with the potential between 0.7 V
and 1.2 V to check the remnant Fc and aspirin signal using procedures identical to those detailed above. As shown in Fig. 8 and
Supplementary Figure S3, the SWV curves and current peak of the
GC-ph-STR-aptamer(aspirin) devices against the implantation time
in LPS-treated rats display dramatic peak current drops with time
extension. The gradually decrease in the Fc and aspirin signals,
respectively, demonstrated the speciﬁc detection of our sensor
of inﬂammation (i.e., IFN-γ expression) and the inﬂammationtriggered aspirin release. Moreover, the difference in peak current
between the untreated electrode (from the original aspirin) and
the withdrawn electrodes (from the remnant aspirin) was used to
calculate the percentage of aspirin release during the treatment.
The consequence of the in vivo binding of IFN-γ on the GCph-STR-aptamer(aspirin) electrode was the immediate release of
aspirin. The relationship between the release percentage of aspirin
and the treatment time was also obtained (Fig. 8), revealing the
prospect of the sensor for in vivo detection and subsequent aspirin
delivery targeted to the treatment of inﬂammation. As shown in
the inset of Fig. 8, the in vivo release eﬃciency of aspirin could
reach up to 85.6% after 24 h. Considering that the body weight of
rats used herein was approximately 180 g, each electrode would
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Fig. 9. (a) The quantiﬁcation of inﬂammatory cells per ﬁeld of lung tissue. (b-c) Expression level of inﬂammatory cytokines (IFN-γ and IL-6) in the interstitial ﬂuid of the lung
tissue by ELISA. (d) Histological analysis indicated that LPS injection caused capillary expansion and congestion, as well as neutrophil inﬁltration into the lung tissue, while
the lung injury was well controlled by applying the electrode. The scale bar is 100 μm. (e) Lung injury score increased signiﬁcantly after LPS administration and signiﬁcantly
reduced after electrode treatment (∗ ∗ , p < 0.01 compared with the LPS group). (f) Immunohistochemically identiﬁed neutrophils in the lung after LPS administration and
electrode treatment. Yellow arrows represent the positive area. The scale bar is 100 μm. (g) Score of Ly-6 G protein expression levels increased in the lung sections of two
groups (∗ ∗ , p < 0.01 compared with the LPS group). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)

release an aspirin level of 2.7 mg/kg in rat blood after 24 h of
implantation. This aspirin concentration was lower than the ideal
amount (10 mg/kg/day) used for traditionally anti-inﬂammatory
treatment in a murine model [42].
3.8. In vivo inﬂammation control using the adaptive
GC-ph-STR-aptamer (aspirin) devices
LPS is the major element of the outer membrane in gramnegative bacteria. LPS-induced endotoxemia can lead to serious
acute lung injury (ALI), which is characterized by an increase in
capillary permeability and neutrophil migration into the lungs
[43]. Moreover, exposure to LPS can induce the secretion of additional proinﬂammatory cytokines, resulting in the activation of
polymorphonuclear neutrophils (PMNs) and further inﬂammatory
responses in the lung [44]. To demonstrate the performance of
adaptive GC-ph-STR-aptamer(aspirin) in vivo devices, we collected
lungs from the inﬂammatory rat model with and without electrode
implantation for 24 h, and then the quantitative analysis of these
lung samples was performed to provide evidence for the in vivo
therapeutic eﬃcacy of our electrode. As shown in Fig. 9a, the num-

ber of inﬂammatory cells was signiﬁcantly reduced after electrode
administration under LPS treatment condition. In addition, the
ELISA results show that the expression of inﬂammatory cytokines
(IFN-γ and IL-6) in the interstitial ﬂuid obviously deregulated,
indicating the effective inhibition of the inﬂammation (Fig. 9b and
c). These lung samples were also stained with hematoxylin and
eosin (H&E) for histological analysis and neutrophil marker (Ly-6G)
for polymorphonuclear (PMN) leukocyte inﬁltration by immunohistochemistry detection, indicating that PMN cells inﬁltrated
more into the lungs of the untreated group 24 h after LPS injection
than those of the electrode-treated group (Fig. 9d and f). Moreover,
Fig. 9e and g show that the degree of lung injury was signiﬁcantly
improved while the number of neutrophil expression was dramatically reduced after treatment with our electrode, providing further
evidence of the therapeutic eﬃcacy of our electrode.
To further evaluate the therapy, the blood specimens of the
electrode-treated and untreated inﬂammatory rat model were collected for the measurement of the inﬂammatory cytokines IFN-γ
and IL-6. As shown in Fig. 10, the levels of inﬂammatory cytokines
(IL-6 and IFN-γ ) in the electrode-treated rats have no obvious
change within 24 h after LPS injection, which is in accordance with
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Fig. 10. The inﬂammation induced by LPS (control, untreated group) was inhibited by the GC-ph-STR-aptamer(aspirin) sensor (electrode-treated group) or pure aspirin
(aspirin-treated group). The concentration of IFN-γ (a) and IL-6 (b) was measured in the serum of the inﬂammatory rat model with and without treatments.

the pure aspirin-treated rats. However, the concentration of both
inﬂammatory cytokines in rats without treatment dramatically increased only in several hours. This indicates that the inﬂammation
could be effectively and consistently suppressed by application of
our electrodes. These results revealed that this adaptive GC-phSTR-aptamer(aspirin) in vivo device could achieve the on-demand
release of aspirin to effectively inhibit inﬂammation.
4. Conclusions
Cytokines, the signaling molecules in the immune system, play
a key role in mediating and controlling immune and inﬂammatory responses. [45] Complex interactions exist among cytokines,
inﬂammation, and the adaptive and innate responses to maintain
normal homeostasis. It is essential to develop accurate and sensitive methods for the measurement of cytokines in real time to
dynamically monitor inﬂammation, and such measurements can
be an important basis for the proper treatment of developing and
ongoing disease. [22,30,46] Recently, there has been increasing
evidence that an abnormal inﬂammatory response is closely associated with various disease conditions. [1] Thus, interest has
been shown toward therapeutically targeting the inﬂammatory
response. Lack of precise, directed application of therapeutics and
reduced effectiveness with chronic use are current limitations for
the treatment of inﬂammation. To overcome these issues, precision or personalized medicine has demonstrated the capability of
diagnosis and triggered treatment by delivering “the right drug, at
the right dose, and at the right time” [6].
On-demand, local delivery of anti-inﬂammatory drugs to target
tissues provides a means for effective drug dosing while reducing
the adverse effects of systemic drug delivery. The study reported
here has demonstrated a proof-of-concept theranostic approach for
inﬂammation based on analyte-kissing-induced signaling whereby
a drug (in this report, aspirin) can be released upon the detection
of a target level of a proinﬂammatory cytokine (i.e., interferon-γ
(IFN-γ )) in real time. The structure-switching aptamer-based
biosensor described here is capable of quantitatively and dynamically detecting IFN-γ both in vitro and in vivo with a sensitivity
of 10 pg mL−1 . Moreover, the released aspirin triggered by the
inﬂammatory cytokine IFN-γ is able to inhibit inﬂammation in a
rat model, and the release of aspirin can be quantitatively controlled. This study is a an advancement of our previous study that
reported a sensitive sensing device for monitoring inﬂammation
in mice. [30] In our previous report, the positively charged redox
probes (ruthenium hexamine), acting as the signaling molecules,

were loaded into the structure-switching aptamers. The presence
of IFN-γ triggers the release of redox probes, resulting in an
electrochemical signal that measures the concentration of IFN-γ .
Although the sensitivity of this sensor is high, this in vivo sensing
device has three limitations: 1) it cannot act as a real-time sensor, 2) the release of redox probes into the mice might cause a
potential safety problem, and 3) it does not have the therapeutic
function of the device reported in this study.
Speciﬁcally, here we prepared the adaptive device based on
the aspirin intercalating hairpin aptamer that can realize the
spatially localized monitoring of IFN-γ in real time along with the
simultaneous delivery of aspirin. Furthermore, the performance of
this adaptive device has been investigated in vitro, in cell culture
medium, in blood samples, and in the serum of LPS-treated rats.
To the best of our knowledge, this is the ﬁrst study to provide
a technology for the in vivo real-time monitoring of proinﬂammatory cytokines and the subsequent therapeutic delivery of
anti-inﬂammatory molecules. Thus, this report provides a new and
promising strategy for the precision theranostic of inﬂammation.
By varying the aptamer probes targeted to different analytes
(such as cancer biomarkers) and also the availability of small
therapeutic drugs (such as doxorubicin), this universal theranostic
platform has signiﬁcant potential for personalized medicine and
the effective treatment of numerous health conditions.
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